TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OSR Holdings ( (OSRH) ) just unveiled an announcement.
On November 21, 2025, OSR Holdings‘ subsidiary, Vaximm AG, entered into a non-binding global license term sheet with BCM Europe AG for the VXM01 oral cancer immunotherapy platform. This agreement outlines the potential for a definitive licensing agreement, with Vaximm set to receive a $20 million upfront payment and up to $815 million in milestone payments. The collaboration aims to accelerate the development and commercialization of VXM01, positioning BCM Europe as a strategic financial intermediary to facilitate a major pharmaceutical partnership. The term sheet includes an exclusivity period for negotiations and introduces an optional blockchain-based royalty participation mechanism.
More about OSR Holdings
OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in healthcare and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve global health outcomes.
Average Trading Volume: 4,271,950
Technical Sentiment Signal: Sell
Current Market Cap: $16.68M
See more data about OSRH stock on TipRanks’ Stock Analysis page.